The effect of luminal ghrelin on pancreatic enzyme secretion in the rat.
Ghrelin, a 28-amino-acid peptide produced predominantly by oxyntic mucosa has been reported to affect the pancreatic exocrine function but the mechanism of its secretory action is not clear. The effects of intraduodenal (i.d.) infusion of ghrelin on pancreatic amylase outputs under basal conditions and following the stimulation of pancreatic secretion with diversion of pancreato-biliary juice (DPBJ) as well as the role of vagal nerve, sensory fibers and CCK in this process were determined. Ghrelin given into the duodenum of healthy rats at doses of 1.0 or 10.0 microg/kg increased pancreatic amylase outputs under basal conditions or following the stimulation of pancreatic secretion with DPBJ. Bilateral vagotomy as well as capsaicin deactivation of sensory fibers completely abolished all stimulatory effects of luminal ghrelin on pancreatic exocrine function. Pretreatment with lorglumide, a CCK(1) receptor blocker, reversed the stimulation of amylase release produced by intraduodenal application of ghrelin. Intraduodenal ghrelin at doses of 1.0 or 10.0 microg/kg increased plasma concentrations of CCK and ghrelin. In conclusion, ghrelin given into the duodenum stimulates pancreatic enzyme secretion. Activation of vagal reflexes and CCK release as well as central mechanisms could be implicated in the stimulatory effect of luminal ghrelin on the pancreatic exocrine functions.
Nawrot-Porabka
Katarzyna
K
Department of Medical Physiology, Faculty of Health Care, Jagiellonian University Medical College, 16 Grzegorzecka Street, 31-531 Cracow, Poland.
Jaworek
Jolanta
J
Leja-Szpak
Anna
A
Szklarczyk
Joanna
J
Macko
Magdalena
M
Kot
Michalina
M
Mitis-Musioł
Małgorzata
M
Konturek
Stanisław J
SJ
Pawlik
Wiesław W
WW
D000681:Amylases / Q000378:metabolism*; D000818:Animals; D002211:Capsaicin / Q000008:administration & dosage / Q000494:pharmacology; D002766:Cholecystokinin / Q000097:blood; D004386:Duodenum / Q000187:drug effects / Q000378:metabolism; D054439:Ghrelin; D006801:Humans; D008297:Male; D010179:Pancreas / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D036361:Peptide Hormones / Q000008:administration & dosage / Q000494:pharmacology*; D011377:Proglumide / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D011863:Radioimmunoassay; D051381:Rats; D017208:Rats, Wistar; D043886:Receptor, Cholecystokinin A / Q000037:antagonists & inhibitors; D014628:Vagotomy
D054439:Ghrelin; D036361:Peptide Hormones; D043886:Receptor, Cholecystokinin A; D002766:Cholecystokinin; D000681:Amylases; D011377:Proglumide; C048181:lorglumide; D002211:Capsaicin